Arrington's Better Deals and Lower Prices Act Passes Ways and Means Committee

The House Committee on Ways and Means passed the H.R. 4822 Health Care Price Transparency Act out of Committee. Included in the package was Rep. Arrington’s H.R. 4846, the Better Deals and Lower Prices Act, a bill that would require pharmacy benefit managers (PBMs) to share net price data from all drugs regardless of class to employers that request it, allowing businesses small and large to access the same information and shop effectively.

Passage of the Better Deals and Lower Prices Act means American businesses and the working families they employ are one step-closer to spending less on drugs and premiums.

To view the Congressman's remarks, click here. For bill text, click here. For a link to the Committee on Ways and Means press release announcing introduction of the Better Deals and Lower Prices Act, click here.

“While America leads in medical innovation and ingenuity, our health care delivery system has fundamental flaws that disadvantage patients and taxpayers alike. By increasing transparency on prescription drug prices, we empower consumers to make informed decisions, inject much-needed competition into the health care market; and ensure taxpayer dollars are being spent in the most cost-effective manner,” said Rep. Arrington. “I’m proud to introduce the Better Deals and Lower Prices Act to arm job creators with the information they need to get the best deal possible and lower prices for their employees, while driving down premiums, and reducing health care costs across the board.”

“Pharmacy benefit managers have come under close scrutiny for how well they truly manage prescription drug benefits for consumers,” said Ways and Means Committee Chairman Jason Smith. “Employers deserve more transparency over how these middlemen operate, so they can better compare options and find competitive offers that meet the needs of their workers. Rep. Arrington’s bill, the Better Deals and Lower Prices Act, will ensure that PBMs can no longer lock customers and businesses out of this important information when deciding which option is best for their employees.”

Background:

• Many companies do not have the resources to negotiate back and forth with drug manufacturers on the cost and quantity of the drugs they require for their employees.

• Traditionally, PBMs filled this function, and while companies don't have to contract with a PBM to develop their drug benefit, virtually all of them do.

• Over time, and due largely to a lack of oversight and transparency, the 3 Largest PBMs have grown to control 90% of the market- while patients and employers face mounting barriers to understanding how PBMs negotiate for them, and whether the deal they're getting is as good as they think.

• This means two things: Companies can't act as rational consumers and compare PBM net price data across the market, or "shop around," and working Americans with employer sponsored insurance (roughly 160,000,000 of them) are paying higher premiums than they need to.